De-Risking Clinical Hepatotoxicity in Early Drug Discovery

De-Risking Clinical Hepatotoxicity in Early Drug Discovery

Hepatotoxicity due to drugs and other xenobiotics, also known as drug-induced liver injury (DILI), is a primary reason for 1) the termination of drug development programs, 2) the delay of approving otherwise efficacious drugs by requiring large and expensive safety-focused clinical trials, 3) the restriction on the clinical use of approved drugs by the inclusion of black box warnings, and 4) the removal of approved drugs from the market.

Ocular Drug Discovery & Development: How Modeling & Simulation is Driving and Optimizing Complex Formulations

Ocular Drug Discovery & Development: How Modeling & Simulation is Driving and Optimizing Complex Formulations

Software: GastroPlus®
Division: PBPK

The development of ophthalmic drug products is challenging due to the complexity of the ocular system, the lack of sensitive testing to evaluate the interplay of its physiology with ophthalmic drugs, and measurement limitations associated with ocular pharmacokinetics.

AI for Pharmacological Modeling

AI for Pharmacological Modeling

Authors: Lu J, Sun T

Pharmacological modeling plays a key role in drug development by guiding decisions on dosing to optimize safety and efficacy and ultimately streamlining the path to successful therapeutic interventions.

Ionization Prediction Summit Webinar Series: Session 1 Fundamentals of Ionization

Ionization Prediction Summit Webinar Series: Session 1 Fundamentals of Ionization

Software: ADMET Predictor®
Division: PBPK

In the Ionization Prediction Summit webinar series, leading industry experts will explain ionization, how ionization modeling works, how ionization models are influenced by the large amounts of industrial data...